Percy Ivy

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

Tracy T. Batchelor, A. Gregory Sorensen, Emmanuelle di Tomaso et al. · Cancer Cell · 2007 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

Tracy T. Batchelor, Dan G. Duda, Emmanuelle di Tomaso et al. · Journal of Clinical Oncology · 2010 · 516 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Amit M. Oza, Laurie Elit, Ming‐Sound Tsao et al. · Journal of Clinical Oncology · 2011 · 338 citations · Full text

Medicine, Oncology, Pharmacology +15

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

Ursula A. Matulonis, Suzanne Berlin, Percy Ivy et al. · Journal of Clinical Oncology · 2009 · 301 citations · Full text

Medicine, Oncology, Pharmacology +11

Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion

A. Gregory Sorensen, Kyrre E. Emblem, Pavlina Polaskova et al. · Cancer Research · 2011 · 294 citations · Full text

Medicine, Neurosurgery, Oncology +17